Ivermectin indications and usage: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Ivermectin}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STROMECTOL (IVERMECTIN) TABLET [MERCK SHARP & DOHME CORP.] | ur...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Indications and Usage== | |||
STROMECTOL is indicated for the treatment of the following infections: | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STROMECTOL (IVERMECTIN) TABLET [MERCK SHARP & DOHME CORP.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd | publisher = | date = | accessdate = }}</ref> | ====Strongyloidiasis==== | ||
Strongyloidiasis of the intestinal tract. STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. | |||
This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies.) | |||
====Onchocerciasis==== | |||
STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus. | |||
This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). | |||
NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STROMECTOL (IVERMECTIN) TABLET [MERCK SHARP & DOHME CORP.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 03:19, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
STROMECTOL is indicated for the treatment of the following infections:
Strongyloidiasis
Strongyloidiasis of the intestinal tract. STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis.
This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Onchocerciasis
STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.
This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C).
NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.[1]
References
Adapted from the FDA Package Insert.